Medical management of pulmonary disease caused by Mycobacterium avium complex

The current medical therapy for Mycobacterium avium complex is controversial. American Thoracic Society recommendations advocate empiric therapy with drug susceptibility testing only for clarithromycin. At National Jewish, where we mainly see cases complicated by treatment failure and drug intoleran...

Full description

Saved in:

Bibliographic Details
Published in:	Clinics in chest medicine Vol. 23; no. 3; p. 633
Main Author:	Iseman, Michael D
Format:	Journal Article
Language:	English
Published:	United States 01.09.2002
Subjects:	Anti-Bacterial Agents Antitubercular Agents - therapeutic use Clinical Trials as Topic Drug Therapy, Combination - therapeutic use Humans Microbial Sensitivity Tests Mycobacterium avium Complex - pathogenicity Mycobacterium avium-intracellulare Infection - drug therapy Mycobacterium avium-intracellulare Infection - microbiology Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - microbiology
ISSN:	0272-5231
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The current medical therapy for Mycobacterium avium complex is controversial. American Thoracic Society recommendations advocate empiric therapy with drug susceptibility testing only for clarithromycin. At National Jewish, where we mainly see cases complicated by treatment failure and drug intolerance, we use in vitro susceptibility testing and therapeutic drug monitoring to optimize efficacy and reduce toxicity.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	0272-5231
DOI:	10.1016/s0272-5231(02)00023-0